|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
|
GALECTIN THERAPEUTICS INC (Name of Issuer) |
COMMON STOCK (Title of Class of Securities) |
(CUSIP Number) |
Richard E. Uihlein 12575 Uline Drive, Pleasant Prairie, WI, 53158 262-612-4200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
07/31/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Richard E. Uihlein | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
54,673,646.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
49.30 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
COMMON STOCK |
| (b) | Name of Issuer:
GALECTIN THERAPEUTICS INC |
| (c) | Address of Issuer's Principal Executive Offices:
4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS,
GEORGIA
, 30071. |
| Item 2. | Identity and Background |
| (a) | Richard E. Uihlein |
| (b) | 12575 Uline Drive, Pleasant Prairie, WI 53158 |
| (c) | None |
| (d) | None |
| (e) | None |
| (f) | United States |
| Item 3. | Source and Amount of Funds or Other Consideration |
Personal Funds | |
| Item 4. | Purpose of Transaction |
The Shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of the Company. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%. |
| (b) | 54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%. |
| (c) | On July 31, 2026, the Reporting person converted debt in the amount of approximately $105.8 (consitsing of $91.0 million of principal and approximately $14.8 million of accrued interest) into 34,376,167 shares of common stock. |
| (d) | None |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
None | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|